Abstract
Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Current Drug Delivery
Title: Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Volume: 3 Issue: 1
Author(s): Rachna Rastogi, Yasmin Sultana, Asgar Ali and Mohammed Aqil
Affiliation:
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Abstract: Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Export Options
About this article
Cite this article as:
Rastogi Rachna, Sultana Yasmin, Ali Asgar and Aqil Mohammed, Particulate and Vesicular Drug Carriers in the Management of Tuberculosis, Current Drug Delivery 2006; 3 (1) . https://dx.doi.org/10.2174/156720106775197448
DOI https://dx.doi.org/10.2174/156720106775197448 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science Polyene Macrolide Antibiotic Biosynthesis
Current Medicinal Chemistry Novel Delivery Systems for Anti-Allergic Agents: Allergic Disease and Innovative Treatments
Current Drug Delivery MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging A Study on the Biological Activity of 2-thioxo-imidazolidin-4-ones
Letters in Drug Design & Discovery Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics QSAR and Docking Studies on Propenone Derivatives as Dual COX and 5- LOX Inhibitors
Letters in Organic Chemistry Imidazole and 1,2,4-Triazole-based Derivatives Gifted with Antitubercular Activity: Cytotoxicity and Computational Assessment
Current Topics in Medicinal Chemistry Challenges Associated with Current and Future TB Treatment
Infectious Disorders - Drug Targets XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?
Recent Patents on Anti-Infective Drug Discovery Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Meldrum's Acid in Organic Synthesis, an Outlook to Reaction Media
Current Organic Chemistry Detection of Antibodies Against Synthetic Peptides Mimicking Ureases Fragments in Sera of Rheumatoid Arthritis Patients
Protein & Peptide Letters Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA HIV Genetic Diversity: Biological and Public Health Consequences
Current HIV Research Identifying the Structural Features of Diphenyl Ether Analogues for InhA Inhibition: A 2D and 3D QSAR Based Study
Letters in Drug Design & Discovery Prediction of Nicotinamide Adenine Dinucleotide Interacting Sites Based on Ensemble Support Vector Machine
Protein & Peptide Letters Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued)